Two Clinical Studies Demonstrate Reduced Surgical Complications & Revision Surgeries With Mazor Robotic Surgical Guidance Sys...
July 19 2016 - 7:54AM
Business Wire
Data Presented at a Leading Spine Conference
Span Almost 850 cases and Validates Clinical Benefit to
Patients
Mazor Robotics, Ltd. (TASE: MZOR; NASDAQ GM: MZOR), a developer
of innovative guidance systems and complementary products, today
announces comprehensive data from two studies demonstrating
significant clinical benefits of its surgical guidance
technological platform. The data was presented during the 23rd
International Meeting on Advanced Spine Techniques (IMAST) annual
meeting in Washington, D.C.
The first study is titled, “Surgical Outcomes of
Robotic-Guidance vs. Freehand Instrumentation – A Retrospective
Review of 705 Adult Degenerative Spine Patients Operated in
Minimally Invasive (MIS) and Open Approaches.” The data showed that
in the hands of experienced MIS surgeons, the use of robotic
guidance in MIS approach can significantly reduce surgical
complications and revision surgeries when compared to fluoro-guided
MIS. The study revealed a three-fold higher rate of complications
in both the freehand MIS and freehand open cases, compared to the
Renaissance-guided cases. The revision rate was 3.8-times higher in
the freehand MIS cases than in the Renaissance MIS cases. All the
results were statistically significant.
The second study, titled: First Report From MIS ReFRESH: A
Prospective, Comparative Study of Robotic-Guidance vs. Freehand
Pedicle Screw Placement in Minimally Invasive Lumbar Surgery
provided data which was reported by Mazor Robotics in May. While
these are preliminary results from an ongoing, prospective,
controlled, multi-center study, data showed that use of Mazor
Robotics surgical guidance in MIS significantly reduced the
complication and revision rates compared to freehand MIS cases.
“Both presented studies demonstrate a significant improvement in
patient outcomes when Renaissance-guidance is utilized by surgeons.
Jointly, the large retrospective data-set corroborates the
preliminary findings of the prospective, controlled study, thus
validating the use of Mazor Robotics guidance technologies in
minimally invasive surgery for patients and surgeons,” said Dr.
Sweeney of the Southeast Spine Center in Sarasota, FL, and one of
the lead investigators of the retrospective study.
“These studies validate the clinical and economic value
proposition of Renaissance by delivering the positive results that
surgeons and hospital administrations expect from advanced
technologies,” commented Ori Hadomi, Chief Executive Officer.
“While MIS adoption for spine surgeries is improving in general,
the rate of MIS surgeries using our surgical guidance technology is
far higher than the industry average, demonstrating that it is an
enabling technology that delivers better patient outcomes,” added
Mr. Hadomi.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing
through innovation by developing and introducing revolutionary
robotic-based technology and products aimed at redefining the gold
standard of quality care. Mazor Robotics Renaissance® Guidance
System enables surgeons to conduct spine and brain procedures in a
more accurate and secure manner. For more information, please visit
www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other securities laws. Any statements in this release about
future expectations, plans or prospects for the Company, including
statements containing the words “believes,” “anticipates,” “plans,”
“expects,” “will” and similar expressions, are forward-looking
statements. These statements are only predictions based on Mazor’s
current expectations and projections about future events. There are
important factors that could cause Mazor’s actual results, level of
activity, performance or achievements to differ materially from the
results, level of activity, performance or achievements expressed
or implied by the forward-looking statements. Those factors
include, but are not limited to, the impact of general economic
conditions, competitive products, product demand and market
acceptance risks, reliance on key strategic alliances, fluctuations
in operating results, and other factors indicated in Mazor’s
filings with the Securities and Exchange Commission (SEC) including
those discussed under the heading “Risk Factors” in Mazor’s annual
report on Form 20-F filed with the SEC on May 2, 2016 and in
subsequent filings with the SEC. For more details, refer to Mazor’s
SEC filings. Mazor undertakes no obligation to update
forward-looking statements to reflect subsequent occurring events
or circumstances, or to changes in our expectations, except as may
be required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160719005818/en/
EVC GroupInvestorsMichael Polyviou,
212-850-6020mpolyviou@evcgroup.comDoug Sherk,
415-652-9100dsherk@evcgroup.comorMediaDavid Schemelia,
646-201-5431dave@evcgroup.com
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mazor Robotics (NASDAQ:MZOR)
Historical Stock Chart
From Apr 2023 to Apr 2024